American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin (2004), 54:8–29., , , et al.
Staging Classifications and Clinical Practice Guidelines of Gynaecological Cancers, 2nd Edition. FIGO Committee on Gynecologic Oncology and IGCS Guidelines Committee, 2003. Reprinted from Int J Gynecol Obstet (2000), 70:207–312., and , eds.
Staging laparotomy in early ovarian cancer. JAMA (1983), 250:3072–6., , , et al.
Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma. Obstet Gynecol (1992), 80:949–53., , , et al.
The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecol Oncol (2001), 82:143–9. and .
Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. Am Coll Surg (2003), 197:198–205., , , et al.
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst (2003), 95:113–25., , , et al.
Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr (1975), 42:101–4..
Reproducibility of tumor measurements in ovarian cancer: a study of interobserver variability. Gynecol Oncol (1994), 55:87–90., , and .
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol (1994), 170:974–9., , , et al.
Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?Am J Obstet Gynecol (1992), 166:504–11., and .
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol (2002), 20:1248–59., , , et al.
Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol (1998), 69:103–8., and .
Survival of patients with epithelial ovarian cancer and the effect of lymphadenectomy in those with stage 3 disease. Aust NZ J Obstet Gynaecol (1999), 39:420–4. and .
Prognostic evaluation of lymphadenectomy for epithelial ovarian cancer. J Surg Oncol (1995), 60:227–31., , , et al.
Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer. Eur J Gynaecol Oncol (1999), 20:361–6., , , et al.
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst (2005), 97:560–6., , , et al.
The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. Br J Cancer (1994), 70:1014–17., , , et al.
National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival. Cancer (1993), 72:3663–70., , , et al.
Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol (2005), 99:447–61., , , et al.
Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1,866 patients. Br J Obstet Gynaecol (1999), 106:1130–6., , , et al.
Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer (1994), 70:363–70., and .
A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol (2000), 78:269–74..
Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol (1983), 61:413–20., , , et al.
The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol (1992), 47:159–66., , , et al.
Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol (2005), 23:8802–11., , , et al.
Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst (2004), 96:1682–91., , , et al.
Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer (2004), 14:42–50., , , et al.
Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol (1991), 42:146–50., , , et al.
Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynaecol Oncol (1996), 17:393–6., , , et al.
Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol (1999), 72:93–9., , , et al.
Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. Int Surg (2002), 87:185–90., , , et al.
Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study. Eur J Gynaecol Oncol (2002), 23:405–10. and .
Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer (2001), 92:2585–91., , , et al.
Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol (2000), 27 (Suppl 7):31–6., , , et al.
Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol (1998), 71:431–6., , , et al.
The influence of pneumoperitoneum used in laparoscopic surgery on an intraabdominal tumor growth. Cancer (1999), 86:770–4., , , et al.
The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer. Gynecol Oncol (2003), 90:431–4., , , et al.
Subcutaneous tumor implantation after laparoscopic procedures in women with malignant disease. Obstet Gynecol (2004), 103:480–7., , , et al.
The incidence of port-site metastases in gynecologic cancers. JSLS (2004), 8:133–9., , , et al.
Trocar site tumor recurrences. May pneumoperitoneum be responsible?Surg Endosc (1998), 12:1294–6., , , et al.
The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer (2004), 101:346–52., , , et al.
Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer. Am J Obstet Gynecol (2005), 193:568–74., , , et al.
Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol (2005), 96:301–6., , , et al.
A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer (2000), 89:1532–40., , , et al.
Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol (1993), 11:166–72., and .
Ovarian cancer: staging with CT and MR imaging. Radiology (1995), 197:619–26., , , et al.
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med (1995), 332:629–34., , , et al.
Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med (2004), 351:2489–97., , , et al.
The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Curr Opin Oncol (2005), 17:505–14. and .
The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer (2000), 88:144–53., and .
Survival time, causes of death, and tumor/treatment-related morbidity in 100 women with ovarian cancer. Hum Pathol (1988), 19:1273–9., , , et al.
The management of ovarian-cancer-caused bowel obstruction. Gynecol Oncol (1981), 12:186–92., , , et al.
Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series. Gynecol Oncol (2003), 89:306–13., , , et al.
Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. The Systematic Review Steering Committee. Gynecol Oncol (1999), 75:313–22., , , et al.
Surgical management of bowel obstruction in advanced ovarian carcinoma. Obstet Gynecol (1983), 61:327–30. and .
A patient's perspective on ovarian cancer as a chronic disease – devaluing a survivor's challenge. Gynecol Oncol (2005), 96:19–20..